Sarah is a Project Director at ANSIRH, leading a phase IV clinical trial on mail-order pharmacy dispensing of mifepristone for medication abortion in the US. She supports new and established abortion providers around the country offer this novel service to their patients and is evaluating the model's feasibility, acceptability, and safety. Sarah is also part of the Nepal Turnaway Study, a longitudinal study investigating the effects of being denied legal abortion care in Nepal. As a PhD candidate in epidemiology at UCSF, Sarah is studying state policies targeting substance use in pregnancy and their impacts on birth outcomes. She received a BA in Development Studies from Brown University and MSc in Global Health from the Harvard School of Public Health.
April 25, 2023
Ehrenreich K, Baba F, Raifman S, Grossman D. Perspectives on Alternative Models of Medication Abortion Provision Among Abortion Patients in the United States. Women's Health Issues. April 2023; https://doi.org/10.1016/j.whi.2023.03.007.
March 21, 2023
Puri M, Raifman S, Daniel S, Karki S, Maharjan D, Chris Ahlbach, Diamond-Smith N, Foster DG. Denial of legal abortion in Nepal. PLOS One. March 2023; https://doi.org/10.1371/journal.pone.0282886.
October 12, 2022
Roberts SCM, Raifman S, Biggs MA. Relationship between mandatory warning signs for cannabis use during pregnancy policies and birth outcomes in the Western United States. Preventative Medicine. October 2022; DOI: 10.1016/j.ypmed.2022.107297.